Viatris (2)

Executive Summary

Viatris is a global healthcare company formed in 2020 through the merger of Mylan and Upjohn, with a mission to empower people worldwide to live healthier at every stage of life. The company operates across the pharmaceutical value chain, focusing on developing, manufacturing, and commercializing a diverse portfolio of generics, complex generics, biosimilars, and branded medicines. With a presence in over 165 countries, Viatris leverages its scale and expertise to provide broad access to high-quality medicines, addressing both chronic and acute conditions. The company's strategy centers on expanding its biosimilar pipeline, optimizing its generic portfolio, and pursuing strategic partnerships to drive growth and improve patient access. Despite facing pricing pressures in the generic market, Viatris maintains a strong operational base and a commitment to sustainability and public health. Its diversified product mix and global footprint position it as a resilient player in the pharmaceutical industry, with opportunities for value creation through innovation and portfolio optimization.

Upcoming Catalysts (preview)

• Q3 2026FDA approval decision for generic version of blockbuster drug60% success
• Q4 2026Launch of new biosimilar in key therapeutic area70% success
• TBDStrategic partnership or acquisition in emerging markets50% success